Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights
May 14, 2018 07:00 ET
|
OptiNose, Inc.
Optinose confirms retail pharmacy availability of XHANCE commenced in early April Company reports more than 1,300 physicians have prescribed XHANCE through the Xperience program YARDLEY, Pa., May ...
Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018
May 07, 2018 08:00 ET
|
OptiNose, Inc.
YARDLEY, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the...
Optinose to Present at Leerink Partners 7th Annual Global Healthcare Conference
February 09, 2018 08:00 ET
|
OptiNose, Inc.
YARDLEY, Pa., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares of Common Stock
October 17, 2017 16:01 ET
|
OptiNose, Inc.
YARDLEY, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by...
Optinose Announces Pricing of Initial Public Offering
October 12, 2017 21:17 ET
|
OptiNose, Inc.
YARDLEY, Pa., Oct. 12, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (Optinose), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by...
InnoPharma Inc. Announces Commercial Launch of Acamprosate Delayed-Release Tablets in the United States
August 15, 2013 08:00 ET
|
InnoPharma, Inc
PISCATAWAY, NJ, Aug. 15, 2013 (GLOBE NEWSWIRE) -- InnoPharma, Inc.
today announced the launch of acamprosate calcium, 333 mg
delayed-release tablets (generic equivalent of
Campral®). ...